National Institutes of Health to Grant Exclusive License for Mesothelin Patent to Cell Genesys, Inc.

Summary

The National Institutes of Health is considering granting an exclusive license to Cell Genesys, Inc. to practice patents related to mesothelin, a differentiation antigen present in mesothelium, mesotheliomas, and ovarian cancers, for use in human gene therapy to treat cancer.